GBG at 2024 ASCO Annual Meeting

Keeping the #ASCO24 slogan „Come from the science, stay for the connection, and leave with an inspiration that will drive you forward”, GBG is taking part in the following presentations this year…

Poster presentations

Poster Session: Developmental Therapeutics – Molecularly targeted agents and tumor biology
June 1, 9:00 a.m. in Hall A

  • “Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.” Presented by Hope S. Rugo (Poster Bd 174)

Poster Session: Breast Cancer – Local/Regional/Adjuvant
June 2, 9:00 a.m. in Hall A

  • “Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.” presented by Carsten Denkert (Poster Bd 158)
  • “Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.” Presented by Alexios Matikas (Poster Bd 113)

Oral presentation
Oral Abstract Session: Breast Cancer – Metastatic
June 1, 3:00 p.m. in Hall B1 (3:24 p.m.)

  • “First-line inavolisib/placebo + palbociclib + fulvestrant with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.” presented by Dejan Juric. 

Finde more informatione at the Congress website.